BYSI
Price
$0.63
Change
-$0.05 (-7.35%)
Updated
Nov 5 closing price
Capitalization
26M
6 days until earnings call
Intraday BUY SELL Signals
VNDA
Price
$3.59
Change
-$0.29 (-7.47%)
Updated
Nov 5 closing price
Capitalization
217.06M
97 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

BYSI vs VNDA

BYSI vs VNDA Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
BYSI vs. VNDA commentary
Nov 06, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BYSI is a Hold and VNDA is a Hold.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for BYSI with price predictions
Nov 04, 2026

BYSI in upward trend: price rose above 50-day moving average on November 04, 2026

BYSI moved above its 50-day moving average on November 04, 2026 date and that indicates a change from a downward trend to an upward trend. In 35 of 42 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 83%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 30, 2026. You may want to consider a long position or call options on BYSI as a result. In 74 of 89 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 83%.

The Moving Average Convergence Divergence (MACD) for BYSI just turned positive on October 30, 2026. Looking at past instances where BYSI's MACD turned positive, the stock continued to rise in 37 of 50 cases over the following month. The odds of a continued upward trend are 74%.

Following a +55.97% 3-day Advance, the price is estimated to grow further. Considering data from situations where BYSI advanced for three days, in 174 of 217 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.

Bearish Trend Analysis

The 10-day RSI Indicator for BYSI moved out of overbought territory on November 03, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 23 similar instances where the indicator moved out of overbought territory. In 21 of the 23 cases, the stock moved lower in the following days. This puts the odds of a move lower at 90%.

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 44 of 44 cases where BYSI's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 90%.

The 10-day moving average for BYSI crossed bearishly below the 50-day moving average on October 12, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 14 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where BYSI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.

BYSI broke above its upper Bollinger Band on November 02, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for BYSI entered a downward trend on November 02, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 12 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 19 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-0.731) is normal, around the industry mean (2.904). P/E Ratio (-3.720) is within average values for comparable stocks, (-0.738). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.314) among similar stocks. P/S Ratio (31.056) is also within normal values, averaging (440.869).

The Tickeron Price Growth Rating for this company is 87 (best 1 - 100 worst), indicating slightly worse than average price growth. BYSI’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BYSI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

A.I.Advisor
a Summary for VNDA with price predictions
Nov 04, 2026

VNDA's RSI Oscillator ascends from oversold territory

The RSI Oscillator for VNDA moved out of oversold territory on November 04, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 35 similar instances when the indicator left oversold territory. In 30 of the 35 cases the stock moved higher. This puts the odds of a move higher at 86%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

The Moving Average Convergence Divergence (MACD) for VNDA just turned positive on November 04, 2026. Looking at past instances where VNDA's MACD turned positive, the stock continued to rise in 36 of 47 cases over the following month. The odds of a continued upward trend are 77%.

Following a +1.50% 3-day Advance, the price is estimated to grow further. Considering data from situations where VNDA advanced for three days, in 155 of 243 cases, the price rose further within the following month. The odds of a continued upward trend are 64%.

VNDA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on September 30, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on VNDA as a result. In 71 of 95 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 75%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where VNDA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 74%.

The Aroon Indicator for VNDA entered a downward trend on November 04, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 19 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of 53 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.986) is normal, around the industry mean (2.904). P/E Ratio (-0.774) is within average values for comparable stocks, (-0.738). Projected Growth (PEG Ratio) (0.020) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.314) among similar stocks. P/S Ratio (1.378) is also within normal values, averaging (440.869).

The Tickeron Price Growth Rating for this company is 79 (best 1 - 100 worst), indicating slightly worse than average price growth. VNDA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. VNDA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

FUNDAMENTALS RATINGS
BYSI vs VNDA: Fundamental Ratings
BYSI
VNDA
OUTLOOK RATING
1..100
4021
VALUATION
overvalued / fair valued / undervalued
1..100
19
Undervalued
53
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9998
PRICE GROWTH RATING
1..100
8779
P/E GROWTH RATING
1..100
1219
SEASONALITY SCORE
1..100
9050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

BYSI's Valuation (19) in the Pharmaceuticals Major industry is somewhat better than the same rating for VNDA (53) in the Biotechnology industry. This means that BYSI’s stock grew somewhat faster than VNDA’s over the last 12 months.

BYSI's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as VNDA (100) in the Biotechnology industry. This means that BYSI’s stock grew similarly to VNDA’s over the last 12 months.

VNDA's SMR Rating (98) in the Biotechnology industry is in the same range as BYSI (99) in the Pharmaceuticals Major industry. This means that VNDA’s stock grew similarly to BYSI’s over the last 12 months.

VNDA's Price Growth Rating (79) in the Biotechnology industry is in the same range as BYSI (87) in the Pharmaceuticals Major industry. This means that VNDA’s stock grew similarly to BYSI’s over the last 12 months.

BYSI's P/E Growth Rating (12) in the Pharmaceuticals Major industry is in the same range as VNDA (19) in the Biotechnology industry. This means that BYSI’s stock grew similarly to VNDA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BYSIVNDA
RSI
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
86%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
76%
Momentum
ODDS (%)
Bullish Trend 2 days ago
83%
Bearish Trend 7 days ago
75%
MACD
ODDS (%)
Bullish Trend 2 days ago
74%
Bullish Trend 2 days ago
77%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
82%
Bearish Trend 2 days ago
77%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
76%
Advances
ODDS (%)
Bullish Trend 4 days ago
80%
Bullish Trend 8 days ago
64%
Declines
ODDS (%)
Bearish Trend 14 days ago
88%
Bearish Trend 11 days ago
74%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
84%
Aroon
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
79%
COMPARISON
Comparison
Nov 06, 2026
Stock price -- (BYSI: $0.68 vs. VNDA: $3.88)
Brand notoriety: BYSI and VNDA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: BYSI: 94% vs. VNDA: 120%
Market capitalization -- BYSI: $27.92M vs. VNDA: $217.06M
BYSI [@Biotechnology] is valued at $27.92M. VNDA’s [@Biotechnology] market capitalization is $217.06M. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $139.16B. The average market capitalization across the [@Biotechnology] industry is $2.27B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BYSI’s FA Score shows that 2 FA rating(s) are green while VNDA’s FA Score has 1 green FA rating(s).

  • BYSI’s FA Score: 2 green, 3 red.
  • VNDA’s FA Score: 1 green, 4 red.
According to our system of comparison, BYSI is a better buy in the long-term than VNDA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BYSI’s TA Score shows that 4 TA indicator(s) are bullish while VNDA’s TA Score has 5 bullish TA indicator(s).

  • BYSI’s TA Score: 4 bullish, 6 bearish.
  • VNDA’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, VNDA is a better buy in the short-term than BYSI.

Price Growth

BYSI (@Biotechnology) experienced а +29.46% price change this week, while VNDA (@Biotechnology) price change was -3.00% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -8.72%. For the same industry, the average monthly price growth was -14.23%, and the average quarterly price growth was -21.13%.

Reported Earning Dates

BYSI is expected to report earnings on Nov 11, 2026.

VNDA is expected to report earnings on Feb 10, 2027.

Industries' Descriptions

@Biotechnology (-8.72% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
Interact to see
Advertisement

BYSI and

Correlation & Price change

A.I.dvisor indicates that over the last year, BYSI has been loosely correlated with GOSS. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if BYSI jumps, then GOSS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BYSI
1D Price
Change %
BYSI100%
+9.34%
GOSS - BYSI
38%
Loosely correlated
+7.22%
CYTK - BYSI
37%
Loosely correlated
+2.07%
VNDA - BYSI
33%
Poorly correlated
+3.47%
TAOX - BYSI
31%
Poorly correlated
-0.37%
RCUS - BYSI
31%
Poorly correlated
+2.12%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
ELV434.1820.43
+4.94%
Elevance Health
TII2.020.06
+3.06%
Titan Mining Corporation
PTCT68.970.85
+1.25%
PTC Therapeutics
ELWT4.17-0.15
-3.47%
Elauwit Connection Inc
NBR76.00-5.22
-6.43%
Nabors Industries Ltd